A phase II trial to assess the impact of b2 adrenergic blockade in immune checkpoint inhibitor (ICI)- refractory metastatic triple negative breast cancer (mTNBC)

被引：0
|
作者：
Gandhi, Shipra [1 ]
Roy, Arya Mariam [1 ]
Minderman, Hans [1 ]
Rosario, Spencer [1 ]
Repasky, Elizabeth A. [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1141
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of RAMO I plus carhoplatin in patients with triple-negative metastatic breast cancer
    Singh, J. C.
    Stein, S.
    Volm, M.
    Smith, J. A.
    Novik, Y.
    Speyer, J. L.
    Adams, S.
    Meyers, M. I.
    Muggia, F.
    Schneider, R.
    Formenti, S.
    Davis, S.
    Choi, H.
    Tiersten, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [42] A Phase II trial of doxil, carboplatin and bevacizumab in metastatic triple negative breast cancer and molecular correlates of response
    Hirshfield, Kim M.
    Lu, Shou-En
    Wong, Serena
    Tan, Antoinette
    Kirstein, Laurie
    Kearney, Thomas
    Shih, Weichung
    Ganesan, Shridar
    Toppmeyer, Deborah L.
    CANCER RESEARCH, 2015, 75
  • [43] A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)
    McArthur, H. L.
    Barker, C. A.
    Gucalp, A.
    Zapata, L. Lebron
    Wen, Y. H.
    Phung, A.
    Wilgucki, M.
    Henrich, M.
    Arnold, B. B.
    Zhang, Z.
    Ho, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Phase 1b/2 Study to Evaluate Eribulin Mesylate (ERI) in Combination with Pembrolizumab (PEM) in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
    Tolaney, Sara
    Savulsky, Claudio
    Aktan, Gursel
    Xing, Dongyuan
    Almonte, Ana
    Karantza, Vasiliki
    Janevski, Mile
    Diab, Sami
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 122 - 122
  • [45] Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
    Daniel G. Stover
    Carlos R. Gil Del Alcazar
    Jane Brock
    Hao Guo
    Beth Overmoyer
    Justin Balko
    Qiong Xu
    Aditya Bardia
    Sara M. Tolaney
    Rebecca Gelman
    Maxwell Lloyd
    Yu Wang
    Yaomin Xu
    Franziska Michor
    Vivian Wang
    Eric P. Winer
    Kornelia Polyak
    Nancy U. Lin
    npj Breast Cancer, 4
  • [46] Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
    Stover, Daniel G.
    Del Alcazar, Carlos R. Gil
    Brock, Jane
    Guo, Hao
    Overmoyer, Beth
    Balko, Justin
    Xu, Qiong
    Bardia, Aditya
    Tolaney, Sara M.
    Gelman, Rebecca
    Lloyd, Maxwell
    Wang, Yu
    Xu, Yaomin
    Michor, Franziska
    Wang, Vivian
    Winer, Eric P.
    Polyak, Kornelia
    Lin, Nancy U.
    NPJ BREAST CANCER, 2018, 4
  • [47] A phase 2 study of pembrolizumab (MK-3475) monotherapy for metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086
    Adams, S.
    Card, D.
    Zhao, J.
    Karantza, V.
    Aktan, G.
    CANCER RESEARCH, 2016, 76
  • [48] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A case of metastatic triple negative breast cancer patient with BRCA2 pathogenic variant who administered PARP inhibitor prior to immune-checkpoint inhibitor and chemotherapy
    Haruko Takuwa
    Shoko Sasaki
    Naoki Goda
    Megumi Takeuchi
    Discover Medicine, 1 (1):
  • [50] Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
    Leonie Voorwerk
    Maarten Slagter
    Hugo M. Horlings
    Karolina Sikorska
    Koen K. van de Vijver
    Michiel de Maaker
    Iris Nederlof
    Roelof J. C. Kluin
    Sarah Warren
    SuFey Ong
    Terry G. Wiersma
    Nicola S. Russell
    Ferry Lalezari
    Philip C. Schouten
    Noor A. M. Bakker
    Steven L. C. Ketelaars
    Dennis Peters
    Charlotte A. H. Lange
    Erik van Werkhoven
    Harm van Tinteren
    Ingrid A. M. Mandjes
    Inge Kemper
    Suzanne Onderwater
    Myriam Chalabi
    Sofie Wilgenhof
    John B. A. G. Haanen
    Roberto Salgado
    Karin E. de Visser
    Gabe S. Sonke
    Lodewyk F. A. Wessels
    Sabine C. Linn
    Ton N. Schumacher
    Christian U. Blank
    Marleen Kok
    Nature Medicine, 2019, 25 : 920 - 928
12345